Combined genetic analysis of juvenile idiopathic arthritis clinical subtypes identifies novel risk loci, target genes and key regulatory mechanisms. Issue 3 (26th October 2020)

• Record Type: Journal Article
• Authors: López-Isac, Elena; Smith, Samantha L; Marion, Miranda C; Wood, Abigail; Sudman, Marc; Yarwood, Annie; Shi, Chenfu; Gaddi, Vasanthi Priyadarshini; Martin, Paul; Prahalad, Sampath; Eyre, Stephen; Orozco, Gisela; Morris, Andrew P; Langefeld, Carl D; Thompson, Susan D; Thomson, Wendy; Bowes, John
• Is Part Of: Annals of the rheumatic diseases. Volume 80:Issue 3(2021)
• Page Start: 321
• Page End: 328
• Publication Date: 2020-10-26
• Subjects: arthritis -- juvenile -- polymorphism -- genetic -- biological therapy; Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2020-218481
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Objectives: Juvenile idiopathic arthritis (JIA) is the most prevalent form of juvenile rheumatic disease. Our understanding of the genetic risk factors for this disease is limited due to low disease prevalence and extensive clinical heterogeneity. The objective of this research is to identify novel JIA susceptibility variants and link these variants to target genes, which is essential to facilitate the translation of genetic discoveries to clinical benefit. Methods: We performed a genome-wide association study (GWAS) in 3305 patients and 9196 healthy controls, and used a Bayesian model selection approach to systematically investigate specificity and sharing of associated loci across JIA clinical subtypes. Suggestive signals were followed-up for meta-analysis with a previous GWAS (2751 cases/15 886 controls). We tested for enrichment of association signals in a broad range of functional annotations, and integrated statistical fine-mapping and experimental data to identify target genes. Results: Our analysis provides evidence to support joint analysis of all JIA subtypes with the identification of five novel significant loci. Fine-mapping nominated causal single nucleotide polymorphisms with posterior inclusion probabilities ≥50% in five JIA loci. Enrichment analysis identified RELA and EBF1 as key transcription factors contributing to disease risk. Our integrative approach provided compelling evidence to prioritise target genes at six loci, highlighting mechanistic insights for the disease biology and IL6ST as a potential drug target. Conclusions: In a large JIA GWAS, we identify five novel risk loci and describe potential function of JIA association signals that will be informative for future experimental works and therapeutic strategies.